News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Study Status:

Closed for enrollment

Contact Information:

(956) 362-2396

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

This is a multicenter, randomized, study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. The primary objectives are to evaluate the safety and efficacy of the vaccine compared to placebo.

Information: 

Principal Investigator
Dynio Honrubia, MD
Co-PI
Luis Cantu Jr.
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC)
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram